Skip to main content

Market Overview

Global Bacteriophage Therapy Market to Surpass US$ 1,652.3 Million by 2030, Says Coherent Market Insights (CMI)

Share:

SEATTLE, June 22, 2021 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global bacteriophage therapy market is estimated to be valued at US$ 1,148.6 million in 2020 and is expected to exhibit a CAGR of 3.7% over the forecast period (2020-2030).

Key Trends and Analysis of the Global Bacteriophage Therapy Market:

Key trends in the global bacteriophage therapy market include increasing prevalence of antibiotic-resistant infections, increasing approvals of novel products, and adoption of inorganic growth strategies by major key players. These key trends are expected to aid in growth of the market.

According to a study report by European Antimicrobial Resistance Surveillance Network (EARS-Net) in 2015, each year, around 33,000 people die in Europe due to anti-microbial resistant infections. According to the National Center for Global Health and Medicine, in 2017, approximately 8,000 individuals died due to drug resistance in Japan.

Request for Sample copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/2752

Moreover, increasing approval and launch of novel products is expected to drive the market growth over the forecast period. For instance, in October 2020, Adaptive Phage Therapeutics received the U.S. Food Drug Administration (FDA)'s orphan drug designation for the treatment of prosthetic joint infections (PJI) utilizing PhageBank.

Furthermore, key players operating in the global bacteriophage therapy market are focusing on adoption of inorganic growth strategies such as acquisitions and collaborations in order to increase their market presence in the global market. For instance, in January 2021, Eligo Bioscience SA entered into a research agreement with GlaxoSmithKline (a pharmaceutical company), for advancing the research and development in Eligobiotics, for the treatment or prevention of acne vulgaris with a CRISPR-based therapeutic, which is a DNA genome known as clustered regularly interspaced short palindromic repeats (CRISPR-Cas3), for strain-specific microbiome modulations.

Key Market Takeaways:

The global bacteriophage therapy market is expected to exhibit a CAGR of 3.7% over the forecast period, owing to the increasing approvals of novel products. For instance, in July 2020, Intralytix, Inc. issued U.S. Patent & Trademark Office (USPTO) for its Shigella bacteriophages and their various applications for improving food safety and human health, including the maintenance of healthy gut microflora by modulating mammal's microbiome and by reducing colonization by Shigella or levels of Shigella in the gut.

Among disease indication, urinary tract infections segment is accounted for largest market share in 2020, owing to rising prevalence of urinary tract infection and development of novel therapies such as bacteriophage therapy for the treatment and management of urinary tract infections. For instance, according to the article published in the National Center for Biotechnology Information in December 2019, the prevalence of urinary tract infection (UTI) in women over 65 years of age is approximately 20%, compared to approximately 11% in the overall population. The report also stated that between 50% - 60% of adult women are expected to observe at least one UTI in their life, while approximately 10% of postmenopausal women reported of facing a UTI in their past.

Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/2752

Competitive Landscape:

Key players operating in the global bacteriophage therapy market include Armata Pharmaceuticals, Inc., Eliava Biopreparations Ltd., Pherecydes Pharma, Intralytix, Inc., Phagelux, Inc., Nextbiotics, InnoPhage, Ltd, Locus Biosciences, Inc., TechnoPhage, Eligo Bioscience SA, Phagomed Biopharma GmbH., PhagePro, Inc., Adaptive Phage Therapeutics, Enbiotix, Inc., Intodeworld, Inc., BiomX Ltd., Phi Therapeutics, Fixed-phage Ltd., Micreos BV, ContraFect Corporation, and OPTIPHARM Co., Ltd.

Market Segmentation:

  • Global Bacteriophage Therapy Market, By Targeted Bacteria:
    • Escherichia coli
    • Staphylococcus Aureus
    • Streptococcus
    • Pseudomonas aeruginosa
    • Salmonella
    • Others
  • Global Bacteriophage Therapy Market, By Disease Indication:
    • Urinary Tract Infections
    • Chronic Otitis
    • Dental Extraction
    • Chronic Ulcerative Colitis
    • Bone Infection
    • Wound and Skin Infections
    • Cystic Fibrosis
    • Others (Eye Infections, Lung Infections, Oral Infections, GI Infections, etc.)
  • Global Bacteriophage Therapy Market, By Route of Administration:
    • Oral
    • Topical
    • Parenteral
  • Global Bacteriophage Therapy Market, By Region:
    • North America
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Country
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Country
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Country
        • South Africa
        • Central Africa
        • North Africa

Related Market Intelligence Reports:

MENA Biologics & Biosimilars Market, by Product Type (Influenza Vaccines, Factor VIII, (Xyntha, Octanate, Kovaltry, Advate, Koate, Adynovate, Kogenate, Hemlibra, Elocta, Recombinate, Feiba, Immunate, Alphanate and Novoeight), Erythropoietin (Epoetin Alfa (Binocrit(2000IU and 4000IU) (Eprex (2000IU and 4000IU) Darbepoietin Alfa (Aranesp) and Epoetin Alfa-epbx (Retacrit, Recormon)), Aflibercept (EYLEA), and Ziv-Aflibercept (ZALTRAP)), by Therapeutic Application (Hemophilia, Age-related Macular Degeneration, Kidney Diseases, Influenza, and Others), and by Region/Country (Gulf and Egypt) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

Read more: https://www.coherentmarketinsights.com/market-insight/mena-biologics-and-biosimilars-market-4393

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide.

Follow Us: LinkedInTwitter


Contact Us:

Mr. Shah
Senior Client Partner – Business Development
Coherent Market Insights

Phone:
US: +1-206-701-6702
UK: +44-020-8133-4027
Japan: +81-050-5539-1737
India: +91-848-285-0837
Email: sales@coherentmarketinsights.com
Website: https://www.coherentmarketinsights.com

Primary Logo

View Comments and Join the Discussion!
 

Latest Ratings

StockFirmActionPT
WPCRBC CapitalInitiates Coverage On89.0
MANBarclaysDowngrades120.0
HIMXVertical ResearchDowngrades7.5
CNRRBC CapitalUpgrades168.0
FIVNPiper SandlerUpgrades200.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com